Illumina introduced DRAGEN v4.5, a comprehensive upgrade to its flagship bioinformatics platform that powers genomic and multi‑omics analyses. The new version incorporates a pangenome reference and default personalization, allowing the software to adapt to individual genomes and improve variant calling in complex regions. Machine‑learning models have been added to enhance somatic analysis, oncovirus detection, and to reduce false positives in FFPE samples—achieving more than a 90% drop in SNV false positives and an 87% reduction in indel errors compared with the previous release.
The update also expands support for Illumina’s TruPath Genome and 5‑base assays. For TruPath Genome, DRAGEN v4.5 resolves challenging-to‑map regions and improves analysis of 15 highly homologous, medically relevant genes. The 5‑base solution now benefits from structural‑variant calling and higher small‑variant accuracy, enabling integrated genetic and epigenetic insights from a single assay. These enhancements are expected to accelerate research in rare disease, oncology, and epigenomics by delivering faster, more accurate results across a broader range of sample types.
Rami Mehio, Senior Vice President and General Manager of BioInsight, noted that the new features “expand the scope of biological questions researchers can address across germline, oncology, and multi‑omic applications—while maintaining the speed, scale, and operational consistency expected from DRAGEN.” The release positions Illumina to maintain its leadership in bioinformatics while meeting growing demand for high‑precision, multi‑omic data analysis.
The 20% reduction in germline small‑variant errors relative to DRAGEN v4.4 and the significant improvements in FFPE sample analysis underscore the platform’s growing accuracy. By integrating these capabilities with Illumina’s latest assay technologies, the company strengthens its competitive advantage and supports its broader strategy of making bioinformatics accessible, reliable, and scalable for researchers and pharmaceutical partners.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.